Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Global Blood Therapeutics (GBT) stocks in Canada

Learn how to easily invest in Global Blood Therapeutics stocks.

Global Blood Therapeutics (GBT) is a leading biotechnology business based in the US. It opened the day at $34.2 after a previous close of $34.13. During the day the price has varied from a low of $33.99 to a high of $35.14. The latest price was $34.9 (25 minute delay). Global Blood Therapeutics is listed on the NASDAQ and employs 389 staff. All prices are listed in US Dollars.

How to buy shares in Global Blood Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GBT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Global Blood Therapeutics stock price (NASDAQ:GBT)

Use our graph to track the performance of GBT stocks over time.

Global Blood Therapeutics shares at a glance

Information last updated 2021-07-09.
Previous close$34.13
Change $0.77
Change % 2.2561%
Volume 523,867
Information last updated 2022-01-25.
52-week range$24.61 - $52.49
50-day moving average $29.63
200-day moving average $32.55
Wall St. target price$68.30
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.45

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Global Blood Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Global Blood Therapeutics price performance over time

Historical closes compared with the close of $34.9 from 2022-01-26

1 week (2022-01-18) 27.23%
1 month (2021-12-28) 13.35%
3 months (2021-10-28) -3.94%
6 months (2021-07-28) 23.06%
1 year (2021-01-28) -27.80%
2 years (2020-01-28) -50.46%
3 years (2019-01-28) 44.68
5 years (2017-01-27) 118.13%

Global Blood Therapeutics financials

Revenue TTM $179.9 million
Gross profit TTM $121.8 million
Return on assets TTM -25.51%
Return on equity TTM -72.41%
Profit margin -154.11%
Book value $4.79
Market capitalisation $1.8 billion

TTM: trailing 12 months

Global Blood Therapeutics share dividends

We're not expecting Global Blood Therapeutics to pay a dividend over the next 12 months.

Global Blood Therapeutics share price volatility

Over the last 12 months, Global Blood Therapeutics's shares have ranged in value from as little as $24.61 up to $52.49. A popular way to gauge a stock's volatility is its "beta".

GBT.US volatility(beta: 1.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Global Blood Therapeutics's is 1.2179. This would suggest that Global Blood Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Global Blood Therapeutics overview

Global Blood Therapeutics, Inc. , a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia.

Stocks similar to Global Blood Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site